• Home
  • Search Results

Search Results

Older Adult (65+)
2055 studies match your search
Open

QuantifyHER

This trial seeks to enroll patients diagnosed with HER2-negative (HER2- low or HER2-0)- MBC who are starting treatment with T-DXd. The purpose is to determine if the test used for HER2+ MBC also works for HER2-low MBC. By participating in this trial, you are contributing to information that may improve the care of future patients with HER2-negative (HER2- low or HER2-0)- MBC. This trial does not require additional biopsies. Only tissue left over from a standard-of-care procedure will be used. The study team will access your medical record to review routine imaging test results as well as track your response to your treatment. Your breast cancer care will be managed by your oncologist, and you won't need to interact with the study team for direct care. No extra visits with the study team are required, except possibly for the initial enrollment.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Coming Soon

Tirzepatide in Obesity-Driven Endometrial Cancer

To determine the anti-proliferative effect of tirzepatide on the endometrium of endometrial cancer (EC) patients .

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Uterine (endometrial))
Open

Ketorolac for IUD Pain Control

Are you planning on having an IUD placed? If you are already planning to get an IUD, this study gives the chance to receive extra pain medication during insertion. Everyone will receive standard pain medication, and 2/3 of volunteers will receive extra. We are looking to see if giving ketorolac pills 1-hour vs 2-hours before an IUD decreases pain levels. We would need 3 hours of in-person clinic time from volunteers. Compensation provided.

Age & Gender
  • 18 years ~ 99 years
  • Female, Gender Inclusive
Study Interest
  • Healthy Volunteer or General Population
  • Sexual and/or Reproductive Health
  • Wellness and Lifestyle
  • Women's Health
Open

Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease

If you have protein in the urine and African descent, Hispanic or American Indian you might have a gene call APOL1 contributing kidney disease. This study will test if you have change in the gene. If you do have that change you can participate in this study .

Age & Gender
  • 18 years ~ 67 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Pressure
  • Diabetes
  • Kidneys and Liver
Coming Soon

A study to investigate the safety and efficacy of IOV-3001 in adults with advanced (unresectable or metastatic) melanoma who will receive lifileucel

The purpose of this study is to find the maximum tolerated dose and the recommended Phase 2 dose of IOV-3001 infusion given after lifileucel to participants with advanced (unresectable or metastatic) melanoma who meet the requirements for treatment with lifileucel. The study duration for each participant will be up to about 6 months (Phase 1, Part 1) or 5 years (Phase 1, Part 2) after the lifileucel dose. Study intervention begins with surgery to get a tumor sample that will be used to make lifileucel

Age & Gender
  • 18 years ~ 70 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Melanoma)
Visit Location
Open

Treatment trial for Major Depressive Disorder using non-invasive brain stimulation  

Do you have depression and are currently experiencing depression symptoms? We are conducting a treatment trial to see whether non-invasive brain stimulation that matches your brain waves can improve depression symptoms. This is a randomized controlled trial where participants will be randomly assigned to receive active or placebo (fake) stimulation. Compensation is provided.

Age & Gender
  • 18 years ~ 70 years
  • Male, Female, Gender Inclusive
Study Interest
  • Behavior
  • LGBTQIA+
  • UNC or UNC Health employees
  • and 3 more
Open

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Early-Stage Breast Cancer

Have you been diagnosed with Molecular Low-Risk Early-Stage Breast Cancer? If so, you may be able to take part in a research study using lower dose of tamoxifen, to evaluate if it is a better treatment than usual hormonal therapy in women with low-risk, early-stage breast cancer.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Breast)
  • Women's Health
Open

Heels 2 Participation (H2P) Interviews

Are you an adult with an intellectual disability (ID/D) age 18 to 30 years? Would you and your adult care partner like to participate in a one-hour zoom interview together to answer questions that can help researchers learn about school and community experiences and technology use that helps people with ID/D transition to adulthood? Digitial gift card compensation provided to both participants.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Developmental
Visit Location
100% Remote (online, phone, text)
Coming Soon

The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

The purpose of this study is to estimate the probability of participants being off all anti-cancer treatment (with the exception of endocrine therapy for those with ER+ disease) and free of disease progression 4 years from study entry.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Allogenic CAR-T

Do you have lupus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM)? You may be eligible for a new CAR-T therapy conducted at University of North Carolina at Chapel Hill. Please reach out to learn more about this new innovative treatment.

Age & Gender
  • 18 years ~ 70 years
  • Male, Female, Gender Inclusive
Study Interest
  • Allergy
  • Chronic Conditions
  • Hands and Feet
  • and 5 more
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research